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Abstract: High-altitude maladaptation syndrome chronic mountain sickness (CMS) is
characterised by excessive erythrocytosis and frequently accompanied by accentuated
arterial hypoxaemia. Whether altered autonomic cardiovascular regulation is apparent in
CMS is unclear. Therefore, we assessed integrative control of blood pressure (BP) and
determined basal sympathetic vasomotor outflow and arterial baroreflex function in 8
Andean natives with CMS ([Hb] 22.6{plus minus}0.9g/dL) and 7 healthy highlanders
([Hb] 19.3{plus minus}0.8g/dL) at their resident altitude (Cerro de Pasco, Peru;
4383m). R-R interval (RRI, electrocardiogram), beat-by-beat BP
(photoplethysmography) and muscle sympathetic nerve activity (MSNA;
microneurography) were recorded at rest and during pharmacologically-induced
changes in BP (modified Oxford test). Although [Hb] and blood viscosity (7.8{plus
minus}0.7 vs 6.6{plus minus}0.7cP; d=1.7, P=0.01) were elevated in CMS compared to
healthy highlanders, cardiac output, total peripheral resistance and mean BP were
similar between groups. The vascular sympathetic baroreflex MSNA set-point (i.e. MSNA
burst incidence) and reflex gain (i.e. responsiveness) were also similar between groups
(MSNA set-point; d=0.75, P=0.16, gain; d=0.2, P=0.69). In contrast, in CMS the
cardiovagal baroreflex operated around a longer RRI (960{plus minus}159 vs 817{plus
minus}50msec; d=1.4, P=0.04) with a greater reflex gain (17.2{plus minus}6.8 vs
8.8{plus minus}2.6msec·mmHg-1; d=1.8, P=0.01) versus healthy highlanders. Basal
sympathetic vasomotor activity was also lower compared to healthy highlanders
(33{plus minus}11 vs 45{plus minus}13bursts·min-1; d=1.0, P=0.08). In conclusion, our
findings indicate adaptive differences in basal sympathetic vasomotor activity and heart
rate compensate for the haemodynamic consequences of excessive erythrocyte volume
and contribute to integrative blood pressure regulation in Andean highlanders with mild
CMS.
New Findings: What is the central question of this study? Does chronic mountain
sickness (CMS) alter sympathetic neural control and arterial baroreflex regulation of
blood pressure in Andean (Quechua) highlanders? What is the main finding and its
importance? Compared to healthy Andean highlanders, basal sympathetic vasomotor
outflow is lower, baroreflex control of MSNA is similar, supine heart rate is lower, and
cardiovagal baroreflex gain is greater in mild CMS. Taken together, these findings
reflect flexibility in integrative regulation of blood pressure that may be important when
blood viscosity and blood volume are elevated in CMS.
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New findings 24 
 25 
What is the central question of this study? 26 
Does chronic mountain sickness (CMS) alter sympathetic neural control and arterial 27 
baroreflex regulation of blood pressure in Andean (Quechua) highlanders? 28 
What is the main finding and its importance? 29 
Compared to healthy Andean highlanders, basal sympathetic vasomotor outflow is lower, 30 
baroreflex control of MSNA is similar, supine heart rate is lower, and cardiovagal baroreflex 31 
gain is greater in mild CMS. Taken together, these findings reflect flexibility in integrative 32 
regulation of blood pressure that may be important when blood viscosity and blood volume 33 
are elevated in CMS. 34 
Key words: Chronic mountain sickness, excessive erythrocytosis, arterial baroreflex, 35 
muscle sympathetic nerve activity, blood pressure control 36 
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Abbreviations:  38 
CMS: Chronic mountain sickness 39 
BP: Blood pressure  40 
Hb: Haemoglobin concentration  41 
RRI: R-R interval  42 
MSNA: Muscle sympathetic nerve activity  43 
EE: Excessive erythrocytosis   44 
HR: Heart rate 45 
SBP: Systolic blood pressure 46 
DBP: Diastolic blood pressure 47 
MAP: Mean arterial pressure 48 
SV: Stroke volume 49 
Qc: Cardiac output 50 
TPR: Total peripheral resistance  51 
PASP: Pulmonary artery systolic pressure 52 
PE: Phenylephrine  53 
SNP: Sodium nitroprusside 54 
SaO2: Arterial oxygen saturation 55 
PaO2: Arterial oxygen partial pressure   56 
PaCO2: Arterial oxygen partial pressure   57 
  58 
Abstract 59 
High-altitude maladaptation syndrome chronic mountain sickness (CMS) is characterised by 60 
excessive erythrocytosis and frequently accompanied by accentuated arterial hypoxaemia. 61 
Whether altered autonomic cardiovascular regulation is apparent in CMS is unclear. 62 
Therefore, we assessed integrative control of blood pressure (BP) and determined basal 63 
sympathetic vasomotor outflow and arterial baroreflex function in 8 Andean natives with 64 
CMS ([Hb] 22.6±0.9g/dL) and 7 healthy highlanders ([Hb] 19.3±0.8g/dL) at their resident 65 
altitude (Cerro de Pasco, Peru; 4383m). R-R interval (RRI, electrocardiogram), beat-by-beat 66 
BP (photoplethysmography) and muscle sympathetic nerve activity (MSNA; 67 
microneurography) were recorded at rest and during pharmacologically-induced changes in 68 
BP (modified Oxford test). Although [Hb] and blood viscosity (7.8±0.7 vs 6.6±0.7cP; d=1.7, 69 
P=0.01) were elevated in CMS compared to healthy highlanders, cardiac output, total 70 
peripheral resistance and mean BP were similar between groups. The vascular sympathetic 71 
baroreflex MSNA set-point (i.e. MSNA burst incidence) and reflex gain (i.e. responsiveness) 72 
were also similar between groups (MSNA set-point; d=0.75, P=0.16, gain; d=0.2, P=0.69). In 73 
contrast, in CMS the cardiovagal baroreflex operated around a longer RRI (960±159 vs 74 
817±50msec; d=1.4, P=0.04) with a greater reflex gain (17.2±6.8 vs 8.8±2.6msec·mmHg-1; 75 
d=1.8, P=0.01) versus healthy highlanders. Basal sympathetic vasomotor activity was also 76 
lower compared to healthy highlanders (33±11 vs 45±13bursts·min-1; d=1.0, P=0.08). In 77 
conclusion, our findings indicate adaptive differences in basal sympathetic vasomotor activity 78 
and heart rate compensate for the haemodynamic consequences of excessive erythrocyte 79 
volume and contribute to integrative blood pressure regulation in Andean highlanders with 80 
mild CMS.  81 
82 
Introduction 83 
Globally, between 5–10% of the ~140 million people living at high-altitude (>2500m) lack the 84 
ability to cope with chronic hypoxia and develop a progressively incapacitating 85 
maladaptation syndrome termed chronic mountain sickness (León-Velarde et al., 2005). 86 
Chronic mountain sickness (CMS), which is most prevalent in natives of the Andean plateau, 87 
is characterised by excessive erythrocytosis (EE, haemoglobin concentration [Hb] ≥21g/dL 88 
for men, ≥19g/dL for women) and is frequently accompanied by accentuated arterial 89 
hypoxaemia for the resident altitude; and, in more severe stages of the disease, pulmonary 90 
hypertension (León-Velarde et al., 2005). In addition, CMS individuals may present with a 91 
number of clinical symptoms including headache, breathlessness, sleep disturbances, and 92 
cognitive impairment (León-Velarde et al., 2005; Villafuerte & Corante, 2016). Importantly, 93 
CMS is also associated with an increased cardiovascular disease risk (Corante et al., 2018), 94 
which increases with disease severity. Specifically, an increased prevalence of thrombotic 95 
events, stroke, coronary heart disease and systemic and pulmonary hypertension, which can 96 
give rise to cardiac hypertrophy and congestive heart failure, have all been reported in CMS 97 
(Monge, 1942; Peñaloza et al., 1971; Leon-Velarde and Arregui, 1994; Leon-Velarde et al., 98 
2014). Excessive erythrocyte volume and the resulting elevations in haemoglobin and 99 
hematocrit are known to contribute to this increased risk (Corante et al., 2018; Tremblay et 100 
al., 2019). However, several other clinical conditions characterised by sustained hypoxaemia 101 
(i.e. Chronic Obstructive Pulmonary Disease) are often accompanied by arterial baroreflex 102 
dysfunction and elevated sympathetic vasomotor outflow (van Gestel & Steier, 2010; 103 
Andreas et al., 2013). Such changes, which can facilitate increased blood pressure 104 
variability, elevated blood pressure, increased arterial stiffness and vascular dysfunction 105 
(Smit et al., 2002; Hijmering et al., 2002; Swierblewska et al., 2010), can all contribute to the 106 
development of cardiovascular disease. Whether arterial baroreflex dysfunction and elevated 107 
sympathetic vasomotor outflow are also apparent in CMS is unclear.  108 
The arterial baroreflex plays a fundamental role in the control of blood pressure 109 
through its regulation of cardiac pacemaker activity and sympathetic vasomotor outflow. 110 
Previous research has found impaired baroreflex control of R-R interval (RRI) in Andean 111 
highlanders with CMS compared to healthy highlanders (Keyl et al., 2003); however, this is 112 
not a consistent finding (Gulli et al., 2007). Baroreflex control of arterial pressure also occurs 113 
via alterations in sympathetic vasomotor outflow. Previously, no difference in maximum gain 114 
(i.e. responsiveness) of carotid baroreflex control of forearm vascular resistance (index of 115 
sympathetic vasomotor activity) was reported for CMS compared to healthy Andean 116 
highlanders (Moore et al., 2006). Nevertheless, to the best of our knowledge, no direct 117 
measurement of sympathetic vasomotor activity exists for CMS individuals. Whilst plasma 118 
catecholamine concentrations may not accurately represent sympathetic nervous system 119 
activity (Esler, 1988), they are reported to be either elevated (Gamboa et al., 2006) or 120 
unchanged (Antezana et al., 1995) in CMS, indicating either an increased or comparable 121 
global sympathetic activation compared to their healthy Andean counterparts. On one hand, 122 
elevated sympathetic activity might be predicted in CMS if exaggerated arterial hypoxaemia 123 
is present; thus augmenting tonic peripheral chemoreflex activation. On the other hand, a 124 
larger blood volume in CMS (Claydon et al., 2004) might have a sympathoinhibitory effect on 125 
basal MSNA, as shown in healthy individuals at sea-level (Charkoudian et al., 2004; Best et 126 
al., 2014).  127 
In light of the equivocal findings, and absence of microneurographic data for CMS, it 128 
is unclear what effect CMS has on sympathetic neural control and arterial baroreflex 129 
regulation of blood pressure in Andean highlanders. The present study, therefore, aimed to 130 
comprehensively assess integrative regulation of resting blood pressure in Andean 131 
highlanders with CMS, and to compare this with healthy highlanders. To achieve this we 132 
assessed blood volume, basal sympathetic vasomotor outflow, and arterial baroreflex control 133 
of the heart and sympathetic vasomotor outflow. Based upon limited previous reports, we 134 
hypothesised that 1) the vascular sympathetic baroreflex would operate around a higher 135 
MSNA burst incidence for CMS, with no difference in reflex gain (i.e. responsiveness), 136 
compared to healthy highlanders; 2) the cardiovagal baroreflex would operate around a 137 
shorter RRI (higher HR) in CMS with a concurrent reduction in reflex gain, therefore, 3) basal 138 
sympathetic vasomotor outflow and arterial pressure would be elevated for CMS. A 139 
secondary aim was to determine the contribution of the peripheral chemoreflex to basal 140 
MSNA and arterial baroreflex function in CMS.  141 
  142 
Methodology 143 
Ethical approval  144 
This study was part of the Global REACH high-altitude research expedition to the 145 
Universidad Peruana Cayetano Heredia’s Instituto de Investigacions de Altura (4380 m; 146 
Cerro de Pasco, Peru) in July 2018. All experimental procedures had Institutional Review 147 
Board approval from Universidad Peruana Cayetano Heredia (#101686, date of approval 148 
20.02.2018) and conformed to the latest revision of the Declaration of Helsinki, except for 149 
registration in a database. Prior to participation, all experimental procedures were explained 150 
to subjects in writing, and verbally, in their native language, and written informed consent 151 
was provided. Participants took part in a number of other studies; however, care was taken 152 
to ensure adequate recovery between protocols to prevent any potential for confounding 153 
results. Furthermore, the present study addressed a distinct a priori research question.  154 
Participants 155 
Twenty Andean men born at an altitude above 3250 m, permanently residing in the Cerro de 156 
Pasco area and who had at least two previous known generations of high-altitude Andean 157 
ancestry were recruited for the study. None of the subjects had travelled to an altitude lower 158 
than 3000m in the previous six months and did not have a history of working in the mining 159 
industry. None of the participants were taking prescribed medication and had no prior history 160 
of cardiovascular, pulmonary, metabolic, neurological or renal disease. Participants attended 161 
the laboratory on two occasions, with a minimum of 24 hours between visits 1) preliminary 162 
screening visit, and 2) experimental visit.  163 
Preliminary screening visit,  164 
On arrival to the laboratory, participants provided a detailed clinical history and history of 165 
high-altitude residence and ancestral background. A venous blood sample was drawn from 166 
the antecubital vein to measure [Hb], hematocrit and blood viscosity. An arterial blood 167 
sample was drawn from the radial artery (CG), following local anaesthesia (2% lidocaine), to 168 
determine arterial blood gases (PaO2 and PaCO2) and arterial oxygen saturation (SaO2). 169 
Total blood volume (packed cell volume and plasma volume) was determined via the 170 
modified carbon monoxide (CO) rebreathing method as previously described in detail 171 
(Schmidt & Prommer 2005) and used previously by our group in lowland and highland 172 
natives at high-altitude (Stembridge et al., 2018, 2019). Participants also performed an 173 
incremental exercise test (20 W/min) to exhaustion, in the semi recumbent position, on an 174 
electronically braked cycle ergometer (Lode Angio; Lode). Breath-by-breath respiratory data 175 
were collected throughout (Oxycon Mobile; Carefusion) to determine peak oxygen 176 
consumption (VO2peak). 177 
Chronic mountain sickness scores were calculated using the Qinghai CMS questionnaire 178 
based on the presence and severity of eight signs and symptoms of CMS, as agreed by 179 
international consensus (León-Velarde et al., 2005); EE, heart palpitations, difficulty 180 
sleeping, cyanosis, parathesia, headache, tinnitus and dilated veins. A value of zero was 181 
assigned to negative answers. Positive answers were categorised as light, moderate, or 182 
severe and assigned values of one, two and three respectively. The sum of assigned values 183 
constituted the CMS score. Subjects were diagnosed with CMS by a score ≥5 in the 184 
presence of EE ([Hb] ≥21g/dL) and individuals not meeting these criteria were categorised 185 
as healthy highlanders. The sum of the score defines CMS severity as absent (0–5), mild (6–186 
10), moderate (11–14) or severe (≥ 15). Two highlanders (both CMS) were current smokers, 187 
but refrained from smoking on the day of testing.  188 
Experimental visit 189 
Experimental protocol 190 
All participants were asked to abstain from caffeine, alcohol and vigorous exercise for at 191 
least 24 hours before to the experimental session and arrived at the laboratory a minimum of 192 
4 hours after a light meal. Following arrival at the laboratory, subjects rested in the supine 193 
position and an antecubital venous cannula was inserted for subsequent drug administration. 194 
Following instrumentation, acquisition of an acceptable MSNA signal and a period of 195 
stabilisation, 10 minutes of baseline data were recorded to determine resting cardiovascular 196 
and pulmonary haemodynamics and sympathetic vasomotor activity. A modified Oxford test 197 
was then performed to assess vascular sympathetic and cardiovagal baroreflex function. 198 
Following baseline measurements, participants were then transferred to breathing 100% O2, 199 
in an attempt to eliminate peripheral chemoreceptor drive, as used previously (Simpson et 200 
al., 2019). Subjects breathed hyperoxia, via a mouthpiece, for a period of five minutes. 201 
Following five minutes of hyperoxia, a second modified Oxford test was performed, whilst 202 
subjects continued to breathe hyperoxia, in order to determine the influence of the peripheral 203 
chemoreflex on arterial baroreflex function. Due to the unknown time course of recovery 204 
from hyperoxia, the order of conditions was not randomised. A minimum of 20 minutes 205 
separated each modified Oxford test.  206 
Experimental measurements 207 
Haematological analysis 208 
Venous blood samples were collected into lithium heparin-coated vacutainers (Becton, 209 
Dickinson and Company, Mississauga, Canada) and tested within 15 minutes of acquisition. 210 
Arterial blood samples were collected into pre-heparinized syringes (safePICO syringes, 211 
Radiometer, Copenhagen, Denmark) for immediate analyses. Whole blood viscosity was 212 
measured in duplicate at a shear rate 225 s-1 at 37 ºC using a cone and plate viscometer 213 
(DV2T Viscometer, Brookfield Amtek, USA) and a circulating water heating bath (TC-150, 214 
Brookfield Amtek, USA). [Hb] and hematocrit, arterial blood gases and SaO2 were 215 
determined by radiometer ABL90 analyzer (ABL90 Flex, Radiometer, Canada). 216 
Cardiovascular haemodynamics 217 
Heart rate and blood pressure were continuously recorded using Lead II electrocardiogram 218 
and finger photoplethysmography (Finometer Pro; Finapres Medical Systems BV, 219 
Amsterdam, The Netherlands). Systolic (SBP), diastolic (DBP) and mean (MAP) pressures 220 
were calculated on a beat-by-beat basis from the finger arterial pressure waveform. 221 
Finometer values were calibrated against the average of three brachial artery blood pressure 222 
measurements taken during baseline. Stroke volume (SV) and cardiac output (Qc) were 223 
estimated using the Model Flow algorithm (Wesseling et al., 1993) and used to estimate total 224 
peripheral resistance (TPR = MAP/Qc).  225 
 226 
Pulmonary Haemodynamics  227 
Echocardiograhy was used to assess pulmonary artery systolic pressure (PASP). Images 228 
were obtained using a commercially available system (Vivid Q, GE, Fairfield, CT, USA) and 229 
stored for subsequent off-line analysis. Pulmonary arterial systolic pressure (PASP) was 230 
quantified as the maximum systolic pressure gradient across the tricuspid valve added to 231 
right atrial pressure estimated from the collapsibility of the inferior vena cava, in line with the 232 
guidelines of the American Society of Echocardiography (Rudski et al., 2010). To derive 233 
pressure, the modified Bernoulli equation (4·V2) was applied to the peak systolic 234 
regurgitation jet velocity measured via continuous wave Doppler (Rudski et al., 2010) 235 
 236 
Muscle sympathetic nerve activity  237 
Multi-unit MSNA was recorded from the peroneal nerve via microneurography as previously 238 
described (Hagbarth & Vallbo, 1968; Sundolf and Wallin, 1978). MSNA signal was confirmed 239 
by pulse-synchronous activity that responded to end-expiratory apnea but not to startle 240 
stimuli or skin stroking. Nerve signals were acquired (Neuroamp EX headstage, 241 
ADInstruments, Sydney, Australia), amplified (100,000x), filtered (band pass 700-2,000Hz), 242 
rectified and integrated (decay constant 0.1s) (LabChart Pro v8.3.1, ADInstruments, Sydney, 243 
Australia). No adverse events or complications occurred during or following the 244 
microneurography procedure in any subject. 245 
 246 
Assessment of Sympathetic and Cardiac Baroreflex function 247 
Baroreflex function was assessed from the MSNA and RRI (and HR) responses during 248 
arterial blood pressure perturbations induced by the modified Oxford  test (Rudas et al., 249 
1999). Briefly, this involved bolus injection of sodium nitroprusside (SNP), followed 90 250 
seconds later by phenylephrine (PE). Prior to experimental testing, bolus doses of SNP and 251 
PE that evoked ~15mmHg perturbations above and below resting arterial blood pressure 252 
were determined for each individual. Briefly, individualized doses of vasoactive drugs were 253 
calculated based on total blood volume (20μg∙L-1 SNP; 30 μg∙L-1 PE), which were adjusted if 254 
insufficient BP perturbations were achieved. Identical doses were administered during all 255 
trials in the same individual. Doses of vasoactive drugs injected were similar in CMS (SNP, 256 
1.66 ± 0.35 μg∙kg-1; PE, 2.48 ± 0.25 μg∙kg-1) and healthy highlanders (SNP, 1.48 ± 0.30 257 
μg∙kg-1, P = 0.30 d = 0.5; PE, 2.34 ± 0.42 μg∙kg-1, P = 0.49 d = 0.42) and induced similar 258 
total blood pressure perturbations in both groups (CMS, 26 ± 5 mmHg; Healthy highlanders, 259 
25 ± 9 mmHg; P = 0.72, d = 0.11). 260 
Data analyses  261 
All haemodynamic data were sampled at 1KHz using a commercial data acquisition software 262 
(LabChart Pro v8.3.1, ADInstruments, Sydney, Australia) and stored on a laboratory 263 
computer for offline analysis. The raw MSNA signal was sampled at 10 KHz. Multi-unit 264 
bursts of MSNA were identified using an automated detection algorithm (Chart Pro 8.3.1) 265 
and confirmed by a trained observer (SAB/LLS), using established criteria (White et al., 266 
2015). To account for sympathetic baroreflex latency, MSNA data were shifted backwards 267 
(Average shift: CMS -1.23 ± 0.05s, healthy highlanders -1.17 ± 0.05s) so that the peak of 268 
each sympathetic burst coincided with the diastolic period which initiated it (Simpson et al., 269 
2019). To account for differences in microelectrode positioning, burst amplitude data were 270 
normalised by assigning a value of 100 to the largest burst observed during baseline. All 271 
other bursts were calibrated against this value. Resting sympathetic vasomotor activity was 272 
quantified as MSNA burst frequency (burst·min-1) and total activity (mean burst amplitude x 273 
burst frequency [au·min-1]) as it reflects the amount of neurotransmitter release and thus 274 
vasoconstrictor drive to the vasculature over a given time period (Charkoudian & Wallin, 275 
2014). 276 
Baroreflex control of MSNA was assessed from the relationship between i) DBP and MSNA 277 
burst probability. DBP was used because MSNA correlates more closely with DBP than SBP 278 
(Sundlof & Wallin, 1978). All DBP values during the modified Oxford test were assigned to a 279 
3 mmHg bin to reduce the statistical impact of respiratory related oscillations (Eckberg & 280 
Eckberg, 1982). The percentage of cardiac cycles associated with a burst of MSNA (ranging 281 
from 0-100%) was calculated for each DBP bin to give values of burst probability. Non-linear 282 
saturation and threshold regions, if present, were excluded through visual inspection of data 283 
points by agreement of two observations. The slope of the linear relationship was 284 
determined by weighted linear regression analysis, and this value provided an index of 285 
vascular sympathetic vascular baroreflex gain. Only slopes with (i) at least five data points 286 
and (ii) R≥ 0.5 were included in the group mean data (Hart et al., 2011). Vascular 287 
sympathetic baroreflex gain for rising and falling pressures were not determined 288 
independently. The operating point of the vascular sympathetic baroreflex was taken as the 289 
average value for MSNA burst incidence (burst·100HB-1) and DBP during the baseline 290 
period before to the modified Oxford test. In contrast to burst frequency, burst incidence, 291 
which is temporally independent, is an index of reflex control and baroreflex ‘gating’ of 292 
sympathetic bursts. Baroreflex control of the heart was assessed from the relationship 293 
between SBP and RRI/ HR during the modified Oxford test. SBP was used as it correlates 294 
more closely with RRI and HR than DBP (Sundlof & Wallin, 1978). Values were averaged 295 
over 3mmHg SBP bins. Baroreflex delays were accounted for by associating SBP values 296 
with either the concurrent heartbeat (resting RRI <800msec, HR <75 bpm,) or subsequent 297 
heartbeat (resting RRI >800msec HR >75bpm) (Eckberg & Eckberg, 1982). Saturation and 298 
threshold regions were excluded by visual inspection, slopes were determined by weighted 299 
linear regression analysis and only slopes with at least five data points and R ≥0.8 were 300 
included in the group mean data (Taylor et al., 2015). To minimize the potential effects of 301 
hysteresis, we restricted data analysis to the rising arm of SBP and used values from the 302 
nadir to the peak SBP response (Hunt & Farquhar, 2005). The operating point was taken as 303 
the average values for RRI/HR and SBP during the resting period prior to the modified 304 
Oxford test.  305 
 306 
Statistical analyses 307 
Differences between groups (CMS vs. healthy highlanders) and between conditions 308 
(baseline vs. hyperoxia) were assessed using pre-planned contrasts. To address hypothesis 309 
1, 2 and 3, differences in arterial baroreflex function, basal sympathetic vasomotor activity 310 
and arterial pressure, between CMS and healthy highlanders, were assessed using 311 
independent T-tests. To address our secondary aim and examine the contribution of the 312 
peripheral chemoreflex mechanism, differences in arterial baroreflex function, sympathetic 313 
vasomotor activity and arterial pressure in CMS and healthy highlanders between baseline 314 
and hyperoxia were assessed using dependent T-tests. Significant cardiovagal baroreflex 315 
slopes (R ≤ 0.8) were not obtained in one CMS participant and one healthy highlander; 316 
therefore cardiovagal baroreflex gain analyses at baseline were based on seven CMS 317 
participants and six healthy highlanders. As a result of MSNA signal losses, repeated 318 
measures comparisons for cardiovascular haemodynamics and sympathetic neural activity 319 
during hyperoxia were performed on six CMS participants and six healthy highlanders. 320 
Furthermore, during hyperoxia, cardiovagal baroreflex slopes did not meet the inclusion 321 
criteria (R ≤ 0.8) in one out of six healthy highlanders; therefore, repeated measures 322 
comparisons for cardiovagal baroreflex gain are limited to five healthy highlanders and six 323 
CMS individuals. Multiple t-tests were chosen to maximize the number of subjects included 324 
in statistical analyses. To correct for multiple comparisons, a priori alpha was adjusted, using 325 
the experiment-wise error rate (Hinkle et al., 2003) as used previously (Busch et al., 2017; 326 
Simpson et al., 2019). Statistical significance was set at P < 0.05. Furthermore, due to a 327 
small sample size, Cohen’s d effect sizes are also reported with d ≥ 0.8 indicative of large 328 
effects (Cohen., 1988). Normality was assessed using Shapiro-Wilk test, and data that was 329 
not normally distributed underwent log10 transformation prior to analysis. All statistical 330 
analyses were performed using Prism 7.03 (GraphPad software, USA). Data are presented 331 
as means ± SD. Differences between groups and conditions are also reported as mean 332 
difference and (95% confidence interval). 333 
 334 
  335 
Results 336 
Participant characteristics 337 
Although twenty participants were recruited for the study; an MSNA signal could not be 338 
obtained in five of them; therefore data is presented for fifteen participants. We tested eight 339 
CMS individuals with a mean ± SD CMS score of 8 ± 2 (range 5–11) and seven healthy 340 
highlanders with a CMS score of 1 ±1 (range 0–3). Seven CMS participants were classified 341 
as having mild CMS and one was classified as having moderate CMS. CMS participants 342 
were similar in age (40 ± 12 yrs), weight (69 ± 12 kg), height (1.61 ± 0.06 m) and body mass 343 
index (BMI; 26.4 ± 4.9 kg∙m-2) to healthy highlanders age (45 ± 12 yrs; d = 0.42, P = 0.39), 344 
weight (71 ± 11 kg; d = 0.18, P = 0.79), height (1.61 ± 0.03 m; d = 0, P = 0.97), BMI (26.5 ± 345 
3.8 kg∙m-2; d = 0.21, P = 0.74). VO2peak values were also similar in CMS and healthy 346 
highlanders (32.9 ± 10.5 vs 28.7 ± 8.8 mL∙kg-1∙min-1; d = 0.43, P = 0.49) 347 
Resting cardiovascular haemodynamics, basal sympathetic neural activity  348 
SaO2 and PaO2 were lower and PaCO2 was higher in CMS compared to healthy highlanders 349 
(Table 1). As expected, haemoglobin concentration, haematocrit and blood viscosity (7.8 ± 350 
0.7 vs 6.6 ± 0.7 cP; d = 1.7, P = 0.01) were all higher in CMS (Table 1). Although not 351 
statistically significant, total blood volume tended to be larger in CMS compared to healthy 352 
highlanders (101 ± 25 vs 85 ± 16 mL·kg-1; d = 0.8, P = 0.2), which was due to a larger total 353 
red blood cell volume, with a similar plasma volume between groups (Table 1, Figure 1). 354 
CMS also tended to exhibit a greater SV (76 ± 13 vs 64 ± 19 mL; d = 0.8, P = 0.32,) and had 355 
a lower HR (64 ± 10 vs 74 ± 4 bpm; d = 1.4, P = 0.03) compared to healthy highlanders, with 356 
a similar Qc in both groups (4.8 ± 0.7 vs 4.7 ± 1.3 L∙min-1; d = 0.1, P = 0.83). TPR was also 357 
similar between CMS and healthy highlanders (19.2 ± 6.2 vs 19.9 ± 5.5); however CMS 358 
exhibited a lower MSNA burst frequency (33 ± 11 vs 45 ± 13 burst·min-1; d = 1.0, P = 0.08) 359 
compared to healthy highlanders (Figure 1). Because Qc and TPR were comparable, MAP 360 
was also similar in CMS compared to healthy highlanders (Figure 1). Unfortunately, due to 361 
the difficulty in identifying the tricuspid value regurgitant jet in four participants we could only 362 
obtain pulmonary artery systolic pressure (PASP) measurements in seven CMS and four 363 
healthy highlanders. PASP values were not significantly different between groups (Table 1). 364 
Arterial baroreflex function 365 
Vascular sympathetic baroreflex gain (i.e. slope of the DBP-MSNA burst probability 366 
relationship) was comparable in CMS and healthy highlanders (-2.5 ± 0.9 vs -2.7 ± 1.1 367 
%·mmHg-1; d = 0.2, P = 0.69, mean diff 0.2 [-0.9 to 1.3]). The operating DBP was also 368 
similar in both groups (71 ± 4 vs 74 ± 9; d = 0.5, P = 0.41, mean diff -3 [-11 to 4]).The MSNA 369 
set-point appeared lower in CMS compared to healthy highlanders (51 ± 12 vs 62 ± 17 370 
bursts∙100Hb-1; d = 0.75, P = 0.16, mean diff -11 [-28 to 8]), although this was not 371 
statistically significant (Figure 2A).  372 
Cardiovagal baroreflex gain (i.e. slope of the relationship between RRI and SBP) was 373 
greater in CMS compared to healthy highlanders (17.2 ± 6.8 vs 8.8 ± 2.6 msec·mmHg-1; d = 374 
1.8, P < 0.01, mean diff 8.4 [2.7 to 15.0]; Figure 2B). These findings were similar regardless 375 
of whether RRI or HR was used. Operating SBP was similar in both groups (CMS, 109 ± 8 376 
vs healthy highlanders, 113 ± 15 mmHg; d = 0.4, P = 0.5, mean diff – 4 [-17 to 8]); however 377 
CMS participants operated around a longer RRI (960 ± 159 vs 817 ± 50 msec; d = 1.4, P = 378 
0.04, mean diff -143 [-7 to -279]; Figure 2).  379 
  380 
 381 
Table 1. Haematological variables and resting pulmonary haemodynamics in CMS (n=8) and 382 
healthy highlanders (n=7). RBC = red blood cell. Data presented as mean ± SD. † Values 383 
based on six CMS and five healthy highlanders ♦ Values based on seven CMS and four 384 
healthy highlanders. Statistical comparisons performed using independent t-tests 385 





P value Cohen’s d 
Mean difference 
(95% CI) 
Haematological variable      
Haemoglobin (g/dL) 22.6 ± 0.9 19.3 ± 0.8 <0.01 3.9 3.3 (2.2 to 4.2) 
Haematocrit (%) 65 ± 5 57 ± 3 <0.01 2.0 8 (3 to 13) 
SaO
2
 (%)† 82 ± 2 87 ± 3 0.01 2.0 -5 (-9 to -2) 
PaO
2
 (mmHg)† 47 ± 2 51 ± 4 0.05 1.4 -4 (-8 to 0) 
PaCO
2
 (mmHg)† 34 ± 1 29 ± 4 0.02 1.9 5 (1 to 9) 
RBC volume (mL·kg-1) 57 ± 14 48 ± 8 0.19 0.8 9 (-5 to 21) 
Plasma volume (mL·kg-1) 41 ± 9 42 ± 9 0.87 0.1 -1 (-11 to 9) 
Pulmonary haemodynamics      
PASP (mmHg) ♦ 29 ± 7 33 ± 7  0.4 0.6 -4 (-14 to 6) 
Table 1.       
 387 
Figure 1. Group mean (±SD) and individual data for haematological and cardiovascular 388 
haemodynamic variables in CMS (n=8) and healthy highlanders (n=7). Blood viscosity 389 
values based on six CMS and five healthy highlanders. Statistical comparisons performed 390 
using independent t-tests. P values are reported with Cohen’s d effect sizes (d) and mean 391 
differences (95% confidence intervals).  392 
 393 
394 
Figure 2. Arterial baroreflex function. Group average regressions between A) diastolic BP 395 
and MSNA burst probability in CMS (n=8) and healthy highlanders (n=7) and B) systolic BP 396 
and R-R interval in CMS (n=7) and healthy highlanders (n=6). The set-points of the vascular 397 
sympathetic and cardiovagal limb of the baroreflex are indicated by the symbols and error 398 
bars (mean ± SD). The arterial baroreflex set points and slopes were compared using 399 
independent t-tests. * P <0.05 versus healthy highlanders. The vascular sympathetic 400 
baroreflex set-point was similar between CMS and healthy highlanders. The slope of the 401 
relationship between diastolic BP and MSNA burst probability was also similar between 402 
groups, indicating no differences in reflex gain. The cardiovagal baroreflex operated around 403 
a similar systolic BP, but a greater RRI set-point in CMS compared to healthy highlanders. 404 
The slope of the relationship between systolic BP and R-R interval was also greater in CMS, 405 
indicating a greater reflex gain. 406 
407 
Arterial baroreflex–peripheral chemoreflex interactions 408 
In CMS participants exposed to 100% O2, HR significantly decreased and Qc also tended to 409 
decrease, although this didn’t achieve significance (d = 0.6, P = 0.07). Oxygen 410 
administration had no effect on any other cardiovascular haemodynamic variable in CMS. 411 
HR and Qc both significantly decreased in healthy highlanders exposed to 100% O2. This 412 
reduction in Qc, was accompanied by an increase in TPR, with no significant effect on BP. 413 
The reduction in HR in both groups was accompanied by a lowering of MSNA burst 414 
frequency, with no effect on burst amplitude (Table 2).  415 
Administration of oxygen had no significant effect on vascular sympathetic baroreflex gain, 416 
operating DBP or MSNA set-point in either CMS or healthy highlanders. Administration of 417 
oxygen had no effect on cardiovagal baroreflex gain (18.8 ± 9.7 to 20.3 ± 7.4 msec·mmHg-1; 418 
d = 0.2, P = 0.7; Figure 3) or operating SBP in CMS, but RRI was longer. In healthy 419 
highlanders administration of oxygen also increased RRI; cardiovagal baroreflex gain was 420 
greater (8.0 ± 2.6 to 14.1 ± 4.9 msec·mmHg-1; d = 1.6, P = 0.01), with no change in 421 
operating SBP (Figure 3). 422 
 423 
 424 
Table 2. Haemodynamics, MSNA and arterial baroreflex function at baseline and during hyperoxia in CMS (n=6) and healthy highlanders (n=6). 425 
Data presented as mean ± SD. Statistical comparisons performed using dependent t-tests. 426 
 
Baseline Hyperoxia  
 
Baseline           Hyperoxia 
  







P value Cohen’s d 
Mean difference 
(95% CI) 
Haemodynamics          
Heart rate (bpm) 60 ± 10 54 ± 14 <0.01 0.5 -6 (-10 to -3) 69 ± 7 61 ± 6 0.03 1.2 -8 (-14 to -1) 
R-R interval (msec) 1019 164 1175 263  0.01 0.7 156 (52 to 262) 880 ± 89 905 ± 100 0.03 0.3 25 (17 to 207) 
Stroke volume (mL) 92 ± 6 93 ± 12 0.95 0.1 0.6 (-16 to 18) 80 ± 21 82 ± 26 0.72 0.1 1.8 (-8 to 12) 
Cardiac output (L·min
-1
) 5.6 ± 1.1 4.9 ± 1.2 0.07 0.6 -0.7 (-1.4 to 0.1) 5.4 ± 1.1 4.9 ± 1.4 0.05 0.4 -0.5 (-0.9 to -0.2) 
TPR (mmHg·L·min
-1
) 16.0 ± 3.2 17.9 ± 4.9 0.18 0.5 1.9 (-1.3 to 5.1) 17.6 ± 5.7 20.5 ± 7.9 0.01 0.4 2.9 (0.3 to) 
Diastolic BP (mmHg) 73 ± 12 71 ± 12 0.20 0.2 -2 (-4 to 1) 74 ± 5 77 ± 6 0.15 0.5 3 (-1 to 6) 
Systolic BP (mmHg) 118 ± 8 115 ±10 0.13 0.3 -3 (-6 to 1) 115 ± 7 120 ± 12 0.13 0.5 5 (-2 to 13) 
MAP (mmHg) 89 ± 9 89 ± 5 0.15 0.2 -2 (-4 to 1) 87 ± 11 92 ± 7 0.11 0.5 3 (-1 to 8) 
Sympathetic neural 
activity 
     
  
   
Burst frequency (burst·min-
1) 
32 ± 13 29 ± 13 0.02 0.7 -3 (-6 to -1) 41 ± 16 33 ± 13 0.04 0.7 -8 (-16 to -0.7) 
Burst incidence 
(bursts·100HB-1) 
51 ± 14 53 ± 13 0.37 0.2 2 (-2 to 5) 60 ± 20 54 ± 21 0.15 0.2 -6 (-13 to 3) 
Normalized burst 
amplitude (au) 
56 ± 8 55 ± 13 0.99 0.2 2 (-10 to 9) 57 ± 5 54 ± 13 0.78 0.2 2 (-10 to 13) 





0.19 0.4 -162 (-473 to 149) 2335 ± 900 1992 ± 1026 0.08 0.4 -343 (-728 to 42) 
Table 2.         
 427 
Figure 3. Cardiovagal baroreflex gain: Individual and group average slopes for the 428 
relationship between RRI and systolic blood pressure at baseline and during hyperoxia in 429 
CMS (n=5) and healthy highlanders (n=6). Administration of oxygen had no effect on 430 
cardiovagal baroreflex gain in CMS but, increased cardiovagal baroreflex gain (8.0 ± 2.6 to 431 
14.1 ± 4.9 msec·mmHg-1; d = 1.6, P = 0.01) in healthy highlanders. Statistical comparisons 432 
performed using dependent t-tests.   433 
Discussion 434 
The major findings of the present study are threefold: i) CMS individuals and healthy 435 
highlanders exhibit similar vascular sympathetic baroreflex gain (i.e. responsiveness), 436 
operating diastolic pressure, and MSNA set-point (i.e. MSNA burst incidence); ii) however, in 437 
mild CMS, the cardiovagal baroreflex operates around a longer RRI (lower heart rate) with a 438 
greater reflex gain; iii) CMS individuals have comparable cardiac output, total peripheral 439 
resistance, and thus, arterial pressure compared to healthy highlanders. However, CMS 440 
individuals exhibit a greater haemoglobin concentration, total blood volume and blood 441 
viscosity, and lower basal vasomotor sympathetic activity (i.e. MSNA burst frequency) 442 
compared to healthy highlanders. Taken together, these findings indicate adaptive changes 443 
in autonomic regulation of blood pressure homeostasis in Andean highlanders with mild 444 
CMS. 445 
Basal sympathetic vasomotor activity in Andeans 446 
The one previous study that has assessed resting sympathetic vasomotor activity in Andean 447 
high-altitude natives found comparable basal MSNA in healthy Bolivian Andeans (Aymara) 448 
and acclimatising lowlanders (Lundby et al., 2018). However, we are the first to assess basal 449 
sympathetic vasomotor activity in Peruvian (Quechua) Andeans, including individuals with 450 
CMS. We observe a 25% lower basal MSNA in CMS compared to healthy highlanders, as 451 
indicated by a reduced MSNA burst frequency (Figure 1). This finding is in contrast to our 452 
hypothesis that basal sympathetic vasomotor activity would be greater in CMS, which was 453 
based upon previous studies reporting either comparable (Antezana et al., 1995) or elevated 454 
(Gamboa et al., 2006) plasma noradrenaline levels in individuals with CMS. A reduced 455 
glomerular filtration rate, (Lozano et al., 1964) and thus noradrenaline clearance, in CMS 456 
would, however, serve to overestimate sympathetic activation using this method, and 457 
potentially explain these contradictory findings. Despite this, it might be anticipated that 458 
sympathetic vasomotor activity would be elevated in CMS individuals due to several factors. 459 
These factors include: exaggerated arterial hypoxaemia (lower PaO2), reports of increased 460 
inflammation and oxidative stress (Bailey et al., 2013, Bailey et al., 2019); and, a reduced 461 
NO bioavailability, all of which exert known sympathoexcitatory effects (Patel et al., 2001). 462 
Sympathetic vasomotor outflow, however, is the net effect of the integration of both 463 
excitatory and inhibitory inputs to the cardiovascular control centres in the brainstem. For 464 
example, elevations in blood volume exert a sympathoinhibitory influence on basal MSNA 465 
(Charkoudian et al., 2004, Best et al., 2014). Notably, CMS individuals in the present study 466 
exhibited a 20% greater blood volume compared to healthy highlanders (Figure 1). Whilst 467 
not statistically significantly different, the effect was large (Cohen’s d = 0.8) and the 468 
differences were comparable to those previously reported in this population (Claydon et al., 469 
2004). Thus, lower basal sympathetic vasomotor activity in CMS could be mediated by an 470 
increase in circulating blood volume. Indeed, we have previously demonstrated a lower 471 
basal sympathetic activity in high-altitude native Sherpa, compared to acclimatising 472 
Lowlanders (Simpson et al., 2019), with Sherpa also exhibiting a greater total blood volume 473 
(Stembridge et al., 2019). Despite this, however, there was no significant correlation 474 
between these factors in the present study (data not shown). It is also important to note, 475 
however, that individuals with CMS were on average ~5 years younger than healthy 476 
highlanders. Although, the reported ~3 bursts·min-1 increase in basal MSNA per decade of 477 
life (Narkiewicz et al., 2005) would not exclusively explain the observed 12 burst·min-1 478 
difference in basal MSNA.   479 
Arterial baroreflex function in Andeans 480 
This is the first study to assess baroreflex control of MSNA in Andean high-altitude natives.  481 
In addition, it is the first to simultaneously assess the vascular sympathetic and cardiovagal 482 
limbs of the arterial baroreflex in the same group. We demonstrated that both CMS and 483 
healthy highlanders exhibit a similar ability to increase and decrease MSNA in response to 484 
transient, pharmacologically induced changes in blood pressure (i.e. the vascular 485 
sympathetic baroreflex gain was unchanged). This is consistent with one previous report of a 486 
similar reflex gain for carotid baroreflex control of forearm vascular resistance (Moore et al., 487 
2006) in both CMS and healthy highlanders. Contrary to our hypothesis, resting heart rate 488 
was lower, and the ability to alter RRI during the modified Oxford test was greater in CMS 489 
compared to healthy highlanders. The operating diastolic pressure for the vascular 490 
sympathetic baroreflex and the operating systolic pressure for the cardiovagal baroreflex 491 
were similar in CMS and healthy highlanders. Furthermore, MSNA burst incidence (i.e. 492 
vascular sympathetic baroreflex set-point) was also not significantly different between 493 
groups, meaning the probability of a burst occurring per cardiac cycle was similar between 494 
CMS and healthy highlanders. Therefore, our data indicate that CMS does not influence the 495 
arterial baroreflex control and gating of sympathetic bursts. Importantly, however, a lower 496 
resting heart rate in CMS reduces the opportunities (i.e. cardiac cycles) for a burst to occur. 497 
Thus, the interaction of a similar MSNA burst incidence (i.e. vascular sympathetic baroreflex 498 
set-point) and lower resting heart in CMS reduces MSNA burst frequency (i.e. basal 499 
sympathetic vasomotor activity). It should be noted that, in contrast to our findings, several 500 
studies report higher, rather than lower, resting heart rates and/or blood pressures for CMS 501 
(Keyl et al., 2003; Claydon et al., 2004; Richalet et al., 2005, Corante et al., 2018). The 502 
reasons for these differences are unclear, although differences in posture, measurement 503 
technique, time of day for measurement, and the duration of the measurement period, all 504 
might contribute. In addition, CMS severity may also be important; indeed, studies that report 505 
higher resting heart rates and blood pressures for CMS also report greater average Hct and 506 
CMS scores than those observed in the present study. Moreover, a positive correlation has 507 
been observed between [Hb] and blood pressure in the Cerro de Pasco population 508 
(Gonzales & Tapia, 2013). Importantly in the present study, cardiac output, total peripheral 509 
resistance, and thus, arterial pressure for CMS are comparable to healthy highlanders; this 510 
is despite greater blood viscosity and total blood volume, secondary to an increase in red 511 
blood cell volume, in CMS. Thus, the lower sympathetic vasomotor outflow and heart rate in 512 
CMS appear to balance the haemodynamic effects of EE, which maintains blood pressure 513 
homeostasis, at least in mild CMS studied here.  514 
Influence of peripheral chemoreflex on arterial baroreflex function in Andeans 515 
Lower PaO2 in CMS individuals would be expected to increase peripheral chemoreflex 516 
activation and potentially reset the arterial baroreflex to operate at higher heart rates, arterial 517 
pressures and level of MSNA (Halliwill and Minson et al., 2002, Steinback et al., 2009). 518 
Importantly, however, peripheral chemoreceptor ventilatory responsiveness to hypoxia is 519 
reported to be blunted in CMS individuals (León-Velarde & Richalet, 2006, Severinghaus et 520 
al., 1966), contributing to alveolar hypoventilation (higher PaCO2) reported in this population 521 
(León-Velarde & Richalet, 2006). Despite a blunted ventilatory responsiveness reported in 522 
CMS the peripheral chemoreflex mechanism did not appear to contribute to the lower HR in 523 
CMS, as acutely eliminating peripheral chemoreceptor drive, via 100% oxygen 524 
administration, had comparable effects on HR in both groups. Interestingly, MSNA burst 525 
incidence remained unchanged for CMS during acute hyperoxia, whilst it was reduced (~ 6 526 
bursts∙100HB-1) for healthy highlanders. However, this reduction in MSNA burst incidence 527 
occurred alongside a small increase in both arterial pressure (~3mmHg) and stroke volume; 528 
therefore, such reductions were likely arterial baroreflex-mediated. In addition, whilst other 529 
hemodynamic responses to hyperoxia were comparable between groups, there was a 530 
significant reduction in TPR in healthy highlanders; this was not observed in CMS. This may 531 
indicate different intrinsic control and regulation of vascular tone; that is healthy highlanders 532 
possess a greater vascular responsiveness to hypoxia compared with CMS. Indeed, this 533 
could contribute, in part, to the observed difference in basal MSNA (i.e. extrinsic control) 534 
under ambient hypoxic conditions. However, any potential difference in local control cannot 535 
be determined from the data presented here. 536 
An inhibitory relationship exists between the peripheral chemoreflex and baroreflex 537 
mechanisms (Somers et al., 1991), whereby an acute increase in peripheral chemoreflex 538 
activation is consistently shown to inhibit baroreflex control of the heart (Heistad & Wheeler, 539 
1971; Sagawa et al., 1997; Steinback et al., 2009; Niewinski et al., 2014; Mozer et al., 2016) 540 
with inconsistent effects on baroreflex control of MSNA (Halliwill & Minson, 2002; Simpson et 541 
al., 2019). In the present study, during ambient air breathing, we observed a greater 542 
cardiovagal baroreflex responsiveness for CMS compared to healthy highlanders. 543 
Furthermore, we observed no change in cardiovagal baroreflex responsiveness for CMS 544 
during acute hyperoxia, but demonstrated a 75% increase in reflex gain for healthy 545 
highlanders. These findings indicate a peripheral chemoreflex-mediated inhibition of 546 
cardiovagal baroreflex responsiveness in healthy Andeans at high-altitude, which does not 547 
appear to be present in CMS. This raises an interesting possibility that whilst a blunted 548 
peripheral chemoreflex responsiveness may contribute to the exaggerated arterial 549 
hypoxaemia in CMS, it may, paradoxically, prevent the reduced cardiovagal baroreflex gain 550 
normally observed during sustained high-altitude exposure (Yazdani et al., 2016; Bourdillon 551 
et al., 2018; Simpson et al., 2019).  552 
Implications 553 
Our findings imply that elevated sympathetic vasomotor outflow and arterial baroreflex 554 
dysfunction do not contribute to the elevated cardiovascular disease risk reported in mild 555 
CMS, since autonomic control of blood pressure is well maintained in the group studied 556 
here. Therefore, other factors may predispose individuals with CMS to cardiovascular 557 
disease. However, we cannot exclude the possibility that elevated sympathetic vasomotor 558 
outflow and/or arterial baroreflex dysfunction may develop in more severe CMS, with 559 
elevated pulmonary arterial pressure (Simpson et al., 2020), which may contribute to the 560 
greater cardiovascular disease risk reported in moderate and severe CMS. 561 
Experimental limitations 562 
There are several limitations in the present study that should be acknowledged. First, due to 563 
time constraints, only small opportunistic samples could be studied. Therefore, meaningful 564 
differences between groups may not have been detected due to low statistical power. 565 
Indeed, insufficient statistical power likely prevented a meaningful 20% difference in both 566 
total blood volume between groups from being detected, despite a similar magnitude of 567 
difference to previous studies (Claydon et al., 2004). Second, given the time constraints 568 
associated with expedition research, it was not possible to control for the time of day that 569 
participants were tested; therefore, diurnal variations in basal MSNA, blood pressure and 570 
cardiovagal baroreflex gain (Taylor et al., 2011) are a consideration in our interpretation. 571 
Notably, our analysis indicates that time of day was not a significant covariate. Third, two 572 
CMS individuals were light to moderate smokers. It is reported that tobacco smoking leads to 573 
increased basal MSNA and attenuates vascular sympathetic baroreflex gain (Middlekauff et 574 
al., 2013), which may have influenced our results. However, this would have potentially 575 
overestimated resting MSNA in CMS, which would not have altered the interpretation of our 576 
results (i.e. lower sympathetic vasomotor outflow in CMS). Fourth, due to a lack of CMS 577 
positive female volunteers, we only studied males; meaning that the findings cannot be 578 
generalised to females, who likely exhibit differences in blood pressure control mechanisms. 579 
Last, we did not assess vascular sympathetic baroreflex gain to rising and falling pressure 580 
independently, due to an insufficient number of data points to construct baroreflex slopes 581 
that met the criteria for inclusion. We acknowledge that this fails to take baroreflex hysteresis 582 
into account (Rudas et al., 1999).  583 
Conclusion 584 
Contrary to our hypotheses, elevated sympathetic vasomotor outflow and arterial baroreflex 585 
dysfunction are not apparent in mild CMS. In fact, basal sympathetic vasoconstrictor drive 586 
and heart rate are lower in CMS, with enhanced cardiovagal baroreflex gain, compared to 587 
healthy highlanders. Such changes appear to be adaptive physiological responses to the 588 
elevations in red blood cell volume, which allow blood pressure homeostasis to be 589 
maintained. Furthermore, whilst a blunted peripheral chemoreflex is reported to be a 590 
possible mechanism responsible for accentuated arterial hypoxaemia in CMS, it may, 591 
paradoxically, augment cardiovagal baroreflex responsiveness compared to healthy 592 
highlanders. 593 
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